Loading...
  • Diagnosis
  • There is a lack of specific approved treatments for TRD and several treatment algorithms have been developed for TRD that also include re-evaluation of initial diagnosis, optimization of initial treatment regimen through switching, augmenting, combination, other mood stabilizers, atypical antipsychotics, thyroid hormones, or monotherapy with second generation antipsychotics. (credenceresearch.com)
  • novel
  • NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2018. (apnews.com)
  • Therefore, there is great need for novel treatment approaches for TRD. (clinicaltrials.gov)
  • There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD. (clinicaltrials.gov)
  • While current treatments are slow to act and only partially effective, new basic and clinical research focusing on the glutamate system is yielding promising new avenues for novel drug discovery. (clinicaltrials.gov)
  • The ineffectiveness of current treatments for major depressive disorder (MDD) coupled with the economic burden associated with the disorder engenders a need for novel therapeutic interventions that can provide greater response and remission rates. (clinicaltrials.gov)
  • Investigator
  • This will be a 2-panel, randomized ( participants are assigned different treatments based on chance), double-blind (neither investigator nor participant knows which treatment the participant receives), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), multicenter study. (clinicaltrials.gov)
  • study
  • This is a randomized, double-blind, active-controlled, 12-week, two-period study consisting of an open-label, bupropion lead-in period, and a double-blind treatment period. (clinicaltrials.gov)
  • The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers. (clinicaltrials.gov)
  • Conclusions This study shows that a minority of Dutch physicians find it conceivable that they would grant a request for EAS from a patient with psychiatric disease, dementia or a patient who is tired of living. (bmj.com)
  • This study aims to evaluate the SERT availability by means of I-123-ADAM SPECT imaging study in drug-free subjects for prognosing MDD treatment and assisting in detecting MDD. (clinicaltrials.gov)
  • The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. (clinicaltrials.gov)
  • This study confirms an imbalanced kynurenine pathway in MDD supporting the hypothesis of a netstimulation of N -methyl- d -aspartic acid (NMDA) receptors in the disorder. (biomedcentral.com)
  • The purpose of this study is to assess the efficacy and safety of multiple doses of vortioxetine, once daily (QD), in participants with major depressive disorder. (clinicaltrials.gov)
  • Drug
  • We announced the newest addition to our CNS portfolio, AXS-12 for the treatment of narcolepsy, which has recently received FDA Orphan Drug designation. (apnews.com)
  • AXS-05 has been granted U.S. Food and Drug Administration (FDA) Fast Track designations for the treatment of TRD and for the treatment of AD agitation. (apnews.com)
  • The chief drawbacks to augmentation or combination strategies are augmented risk of drug interactions, potential decrement in treatment adherence and cost. (credenceresearch.com)